Pantoprazol Hennig (Pantoprazole Sodium Sesquihydrate)

Pantoprazole Sodium Sesquihydrate, the active ingredient in Pantoprazol Hennig, is a proton pump inhibitor presented as a 40 mg tablet for oral use. It reduces stomach acid production and is used to treat acid‑related gastrointestinal conditions in adults and adolescents.

GNH USA supplies Pantoprazol Hennig as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Pantoprazol Hennig is a proton pump inhibitor that acts on the gastric acid secretion pathway. It is indicated for several acid‑related disorders: - Gastro‑oesophageal reflux disease (GERD): provides relief of heartburn and promotes healing of erosive esophagitis. - Erosive gastritis and duodenal ulcer disease: supports ulcer healing by maintaining a low‑acid environment. - Zollinger‑Ellison syndrome: controls excessive gastric acid secretion associated with gastrin‑producing tumours.

Pantoprazol Hennig may cause adverse reactions, most of which are mild and reversible.

Common Side Effects: - Headache: mild to moderate intensity. - Diarrhoea: loose stools without blood. - Nausea: occasional feeling of queasiness. - Abdominal pain: mild cramping. - Flatulence: increased intestinal gas. - Constipation: reduced bowel movements.

Serious or Rare Side Effects: - Severe allergic reaction (anaphylaxis): rash, swelling, difficulty breathing. - Clostridioides difficile infection: persistent watery diarrhoea. - Low magnesium levels (hypomagnesemia): muscle cramps, irregular heartbeat. - Bone fractures: increased risk with long‑term use. - Liver enzyme elevation: abnormal liver function tests. - Acute interstitial nephritis: kidney inflammation presenting with fever and rash.

When prescribing Pantoprazol Hennig, clinicians should consider several safety aspects: - Renal impairment: dose adjustment may be required in severe kidney disease. - Hepatic impairment: monitor liver function in patients with liver disease. - Long‑term therapy: assess need for calcium and vitamin D supplementation to mitigate fracture risk. - Pregnancy and lactation: use only if clearly needed after risk‑benefit evaluation. - Drug interactions: review concomitant medications for potential CYP‑mediated effects. - Store at below 25°C: keep in the original container, protect from moisture and direct sunlight.

Pantoprazol Hennig can affect the pharmacokinetics of several co‑administered drugs.

Major Interactions (Avoid): - Antifungal agents (ketoconazole, itraconazole): reduced absorption due to higher gastric pH. - HIV protease inhibitors (atazanavir, nelfinavir): decreased plasma concentrations.

Moderate Interactions (Monitor Closely): - Clopidogrel: possible reduction in antiplatelet effect. - Warfarin: potential alteration of INR values. - Methotrexate (high dose): increased systemic exposure. - Digoxin: modest increase in serum levels. - Iron supplements: diminished absorption; separate dosing by at least 2 h.